Dr Berdeja presents the latest data at EHA 23 from a clinical trial of bb2121, a second generation CAR T cell for relapser myeloma.
He outlines the patient cohort, noting their heavy pretreatment, and the median progression free survival improvements among best responders.
For more information, watch his interview with ecancer here.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.
